France, Ireland, and Belgium Are the Major Producers on the European Vaccines Market

Pharmaceuticals, Medicinal Chemical And Botanical Products July 12, 2018
Author: Sergey Avramenko
Head of Global Markets Research Team

IndexBox has just published a new report "EU: Vaccines For Human Medicine - Market Report. Analysis And Forecast To 2025". Here is a summary of the report’s key findings.

The Consumption of Vaccines for Human Medicine Is about 8.0 Billion EUR

In 2016, EU vaccines for human medicine market was at 8.0 billion EUR, which was 831 million EUR (or 9%) less than the year before. There was a significant growth by 43% in 2015 due to price increase, after a fluctuations in market volume with an overall upward trend.

France and the UK Were Key Consumers of Vaccines for Human Medicine

The countries with the highest consumption were France (24% of total consumption), the U.K. (24%), Germany (14%), Italy (10%), Poland (7%) and Spain (5%), together comprising near 84% of EU consumption. 

The highest annual growth rates of vaccines for human medicine consumption from 2007 to 2016 were recorded in the U.K., with +18.1% growth. Following significant consumtion growth rates, the U.K. sighnificantly strengthened its share in terms of the EU consumption from 10% in 2007 to 27% in 2016. By contrast, shares of Germany (-8 percentage points) declined over the period under review.

Among the leading consuming countries high levels of per capita consumption levels were recorded in France (29.8 EUR/year in 2016) and the U.K. (29.5 EUR/year) were significantly higher thah the world average of 15.9 EUR/year. 

The Growth in Vaccine Consumption Is Expected to Continue against the Backdrop of the Development of the Health System and Immunization Programs in the EU

Vaccine consumption is mainly formed by state programs for the immunization of the population within the health system. Procurement of vaccines is carried out through special state agencies, and the admission of drugs to the market is strictly regulated by national and international legislation.

Since vaccination plays a crucial role in the health system, and immunization programs in the EU will remain relevant, the demand for vaccines will remain stable. Therefore, it is expected to maintain the current trend of market growth in the medium term. The CAGR of + 4.8% for the nine-year period from 2016 to 2025, which is projected to lead the market value to approx. 12.2 million EUR by the end of 2025.

Vaccines Production Peaked in 2016 at Approx. 11.2 Billion USD

Production of vaccines stood near 11.2 billion EUR in 2016, indicating mixed trend patterns over the last few years. A robust increase over the period from 2009 to 2011 was followed by a gradual decline from 2010-2014. In 2015, however, the EU production soared rapidly and then leveled off in the following year.

France, Ireland, and Belgium Comprised the Majority of Vaccines Output

According to the estimates, the output of the three major producers of vaccines, namely France, Ireland, and Belgium, represent more than three-quaters of EU vaccines output. All the major vaccines manufacturing countries enjoyed a pronounced growth in the output figures. Particularly high were the growth levels in Ireland (+29.3%) and France (+8.5%).

Among EU Members Belgium, France, Ireland and the UK Were the Major Exporting Countries

In 2016, the total exports value for vaccines for human medicine was 17,314 million EUR, 6% less than the year before. In 2016, Belgium (35%), France (17%), Ireland (17%) and the UK (16%) were the main suppliers of vaccines for human medicine in the EU, comprising 85% of total exports. 

Among main exporting countries in EU, Ireland (from 0.04% in 2007 to 17% in 2016) significantly strengthened position in terms of the EU exports, while the shares of other countries showed negative dynamics (excluding the UK and the Netherlands, which remained relatively stable throughout the analyzed period).

Belgium, the UK and France Were the Main Consumers of Vaccines in the EU

In 2016, the total imports value stood at 10,682 million EUR, 22% less than the year before. From 2007 to 2015, EU vaccines for human medicine imports illustrated an upward trend until 2016, when imports of vaccines for human medicine has fallen dramatically.

In 2016, the main import destinations for vaccines for human medicine were Belgium (40%), the UK (18%) and France (11%). The share exported to the UK decreased, while the share of Belgium illustrated a positive dynamic from 2007 to 2016.

Do you want to know more about the European vaccine market? Get the latest trends and insight from our report. It includes a wide range of statistics on

  • vaccine market share
  • vaccine prices
  • vaccine industry
  • vaccine sales
  • vaccine import
  • vaccine export
  • vaccine market forecast
  • vaccine price forecast
  • key vaccine producers

Source: EU: Vaccines For Human Medicine - Market Report. Analysis And Forecast To 2025